Stocksigma LogoStocksigma Logo

NephroPlus Delivers Strong H1FY27 Performance Driven by International Expansion and Volume Growth

NephroPlus reported a 23.6% YoY rise in consolidated H1FY27 revenue to ₹585.2 crore, exceeding guidance, driven by a 12.6% YoY growth in treatments to

NephroPlus Delivers Strong H1FY27 Performance Driven by International Expansion and Volume Growth

Nephrocare Health Services Ltd · Press Release · 03 Nov 2026, 11:48 pm

NephroPlus Delivers Strong H1FY27 Performance Driven by International Expansion and Volume Growth NephroPlus reported a 23.6% YoY rise in consolidated H1FY27 revenue to ₹585.2 crore, exceeding guidance, driven by a 12.6% YoY growth in treatments to 21.01 lakh and a 9.7% YoY increase in revenue per treatment to ₹2,785. Adjusted EBITDA rose 15.3% YoY to ₹134.4 crore, while Adjusted PAT surged 34.7% YoY to ₹76.1 crore with margins expanding 107 bps to 13.0%. For Q2FY27, revenue reached ₹303.4 crore, up 23.5% YoY. The network expanded to 570 clinics across six countries, with international markets contributing ~47% of revenue.

Original exchange filing (PDF)

More announcements from Nephrocare Health Services Ltd

All Nephrocare Health Services Ltd announcements